SSRIs, Psilocybin, MDMA, and Disease Modeling: Strategies to Advance PTSD Treatment
February 24, 2026 Momoko Ishii, Mark Zervas
SSRIs, psilocybin, and MDMA all modulate serotonin-related neural circuits and are used or proposed as treatments for post-traumatic stress disorder (PTSD). Despite their clinical promise, the molecular, cellular, and neural-circuit mechanisms by which they alleviate PTSD symptoms remain poorly understood. This position paper from Zervas Scientific Consulting reviews the neurobiological roles and intellectual property considerations for these compounds, aiming to integrate multidisciplinary knowledge to advance effective novel treatment options for patients with PTSD.